<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl4" position="float">
 <label>Table 4</label>
 <caption>
  <title>Existing Drugs with Therapeutic Potentials for COVID-19 (Drug Repurposing)</title>
 </caption>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">drug candidate</th>
    <th style="border:none;" align="center">CAS RN</th>
    <th style="border:none;" align="center">target</th>
    <th style="border:none;" align="center">possible mechanism of action on COVID-19</th>
    <th style="border:none;" align="center">disease indication</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="left">baricitinib
     <sup>
      <xref ref-type="bibr" rid="ref35">35</xref>
     </sup>
    </td>
    <td style="border:none;" align="left">1187594-09-7</td>
    <td style="border:none;" align="left">JAK kinase</td>
    <td style="border:none;" align="left">a JAK inhibitor that may interfere with the inflammatory processes</td>
    <td style="border:none;" align="left">approved drug for rheumatoid arthritis</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">lopinavir
     <sup>
      <xref ref-type="bibr" rid="ref19">19</xref>
     </sup>
     <xref rid="t4fn2" ref-type="table-fn">a</xref>
    </td>
    <td style="border:none;" align="left">192725-17-0</td>
    <td style="border:none;" align="left">viral proteases: 3CLpro or PLpro</td>
    <td style="border:none;" align="left">protease inhibitors that may inhibit the viral proteases: 3CLpro or PLpro</td>
    <td style="border:none;" align="left">lopinavir and ritonavir are approved drug combination for HIV infection</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">ritonavir
     <sup>
      <xref ref-type="bibr" rid="ref19">19</xref>,
      <xref ref-type="bibr" rid="ref37">37</xref>
     </sup>
     <xref rid="t4fn4" ref-type="table-fn">c</xref>
    </td>
    <td style="border:none;" align="left">155213-67-5</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">darunavir
     <sup>
      <xref ref-type="bibr" rid="ref33">33</xref>
     </sup>
    </td>
    <td style="border:none;" align="left">206361-99-1</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">approved drug for HIV infection</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">favipiravir (favilavir)
     <sup>
      <xref ref-type="bibr" rid="ref29">29</xref>,
      <xref ref-type="bibr" rid="ref36">36</xref>
     </sup>
    </td>
    <td style="border:none;" align="left">259793-96-9</td>
    <td style="border:none;" align="left">RdRp</td>
    <td style="border:none;" align="left">a purine nucleoside that acts as an alternate substrate leading to inaccurate viral RNA synthesis</td>
    <td style="border:none;" align="left">viral infections</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">remdesivir
     <sup>
      <xref ref-type="bibr" rid="ref19">19</xref>,
      <xref ref-type="bibr" rid="ref29">29</xref>,
      <xref ref-type="bibr" rid="ref32">32</xref>
     </sup>
     <xref rid="t4fn2" ref-type="table-fn">a</xref>
    </td>
    <td style="border:none;" align="left">1809249-37-3</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">a nucleotide analogue that may block viral nucleotide synthesis to stop viral replication</td>
    <td style="border:none;" align="left">Ebola virus infection</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">ribavirin
     <sup>
      <xref ref-type="bibr" rid="ref16">16</xref>,
      <xref ref-type="bibr" rid="ref29">29</xref>−
      <xref ref-type="bibr" rid="ref31">31</xref>
     </sup>
     <xref rid="t4fn2" ref-type="table-fn">a</xref>
    </td>
    <td style="border:none;" align="left">36791-04-5</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">RSV infection, hepatitis C, some viral hemorrhagic fevers</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">galidesivir
     <sup>
      <xref ref-type="bibr" rid="ref34">34</xref>
     </sup>
     <xref rid="t4fn3" ref-type="table-fn">b</xref>
    </td>
    <td style="border:none;" align="left">249503-25-1</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">hepatitis C, Ebola virus, Marburg virus</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">BCX-4430 (salt form of galidesivir)
     <sup>
      <xref ref-type="bibr" rid="ref34">34</xref>
     </sup>
     <xref rid="t4fn3" ref-type="table-fn">b</xref>
    </td>
    <td style="border:none;" align="left">222631-44-9</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">hepatitis C, Ebola virus, Marburg virus</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Arbidol
     <sup>
      <xref ref-type="bibr" rid="ref22">22</xref>,
      <xref ref-type="bibr" rid="ref33">33</xref>
     </sup>
     <xref rid="t4fn2" ref-type="table-fn">a</xref>
    </td>
    <td style="border:none;" align="left">131707-23-8</td>
    <td style="border:none;" align="left">S protein/ACE2
     <xref rid="t4fn5" ref-type="table-fn">d</xref>
    </td>
    <td style="border:none;" align="left">an inhibitor that may disrupt the binding of viral envelope protein to host cells and prevent viral entry to the target cell</td>
    <td style="border:none;" align="left">influenza antiviral drug</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">chloroquine
     <sup>
      <xref ref-type="bibr" rid="ref29">29</xref>,
      <xref ref-type="bibr" rid="ref32">32</xref>
     </sup>
    </td>
    <td style="border:none;" align="left">54-05-7</td>
    <td style="border:none;" align="left">endosome/ACE2</td>
    <td style="border:none;" align="left">a drug that can elevate endosomal pH and interfere with ACE2 glycosylation</td>
    <td style="border:none;" align="left">malarial parasite infection</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">nitazoxanide
     <sup>
      <xref ref-type="bibr" rid="ref29">29</xref>
     </sup>
    </td>
    <td style="border:none;" align="left">55981-09-4</td>
    <td style="border:none;" align="left">N/A</td>
    <td style="border:none;" align="left">a drug that may inhibit viral protein expression</td>
    <td style="border:none;" align="left">various helminthic, protozoal, and viral infection-caused diarrhea</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="t4fn2">
   <label>a</label>
   <p>Drugs under clinical trials for treating COVID-19 (repurposing).</p>
  </fn>
  <fn id="t4fn3">
   <label>b</label>
   <p>Drugs under clinical trials for other virus-induced diseases.</p>
  </fn>
  <fn id="t4fn4">
   <label>c</label>
   <p>Ritonavir is a pharmacokinetic profile enhancer that may potentiate the effects of other protease inhibitors due to its ability to attenuate the degradation of those drugs by the liver enzyme CYP3A4 and thus is used in combination with antivirial Lopinavir.
    <sup>
     <xref ref-type="bibr" rid="ref37">37</xref>
    </sup>
   </p>
  </fn>
  <fn id="t4fn5">
   <label>d</label>
   <p>An inhibitor of viral entry to host cells. Its direct action on S protein and ACE2 is yet to be confirmed.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
